Jazz Pharmaceuticals PLC (JAZZ)

Fixed asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	4,068,943	3,992,713	3,909,883	3,843,380	3,834,209	3,794,392	3,762,904	3,738,465	3,659,374	3,583,982	3,481,445	3,300,378	3,094,238	2,863,024	2,625,797	2,436,422	2,363,567	2,279,790	2,216,604	2,188,301
Property, plant and equipment	US$ in thousands	—	—	—	—	—	287,514	298,304	—	301,376	290,067	317,888	341,044	343,423	344,634	426,320	249,601	127,935	128,204	128,259	129,562
Fixed asset turnover		—	—	—	—	—	13.20	12.61	—	12.14	12.36	10.95	9.68	9.01	8.31	6.16	9.76	18.47	17.78	17.28	16.89

December 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $4,068,943K ÷ $—K
= —

The fixed asset turnover of Jazz Pharmaceuticals PLC has shown a fluctuating trend over the reported periods. The ratio measures how efficiently the company is generating revenue from its fixed assets.

From March 31, 2020, to June 30, 2022, the fixed asset turnover steadily increased from 16.89 to 10.95, indicating that the company was able to generate more revenue relative to its investment in fixed assets during this period. This trend suggests improved asset utilization efficiency.

There was a drop in the fixed asset turnover from June 30, 2022, to September 30, 2023, where it fell to 12.36 before increasing to 13.20 by September 30, 2023. This may indicate fluctuations in sales or changes in the value of fixed assets during these periods.

The fixed asset turnover has not been reported for the latter part of 2023 and 2024, which may suggest data unavailability for those periods. It's important to note that a higher fixed asset turnover generally indicates better efficiency in asset utilization, while a decline in the ratio may indicate underutilization of assets or decreased sales generation from fixed assets.

Overall, Jazz Pharmaceuticals PLC has displayed varying levels of efficiency in generating revenue from its fixed assets over the analyzed periods, with some fluctuations observed in the trend.